RAIN - Rain Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-62.64M

Cash

109.8M

Avg Qtr Burn

-16.98M

Short % of Float

9.26%

Insider Ownership

15.24%

Institutional Own.

86.91%

Qtr Updated

03/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Milademetan (RAIN-32) Details Solid tumor/s, Cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Milademetan (RAIN-32) w/ atezolizumab Details Solid tumor/s, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Milademetan (Rain-32) Details Solid tumor/s, Cancer, Carcinoma , Metastatic merkel cell carcinoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Milademetan (Rain-32) Details Liposarcoma, Cancer, Solid tumor/s	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.